Background Background Schizophrenia is
Schizophrenia is associated with widespread cognitive associated with widespread cognitive deficits that have an impact on social deficits that have an impact on social function.Modafinil promotes wakefulness function.Modafinil promotes wakefulness and is reported to enhance cognition. and is reported to enhance cognition.
Aims Aims To study the acute effects of
To study the acute effects of modafinil administration upon brain modafinil administration upon brain activity and cognitive performance in activity and cognitive performance in people with chronic schizophrenia. people with chronic schizophrenia.
Method Method In a randomised double-blind
In a randomised double-blind placebo-controlled crossover design,19 placebo-controlled crossover design,19 patients received either modafinil patients received either modafinil (100 mg) or placebo prior to undertaking (100 mg) or placebo prior to undertaking a working memory task with functional a working memory task with functional magnetic resonance imaging. magnetic resonance imaging.
Results

Results Seventeen patients completed
Seventeen patients completed the study and another underwent acute the study and another underwent acute relapse 4 days post-drug.Modafinil relapse 4 days post-drug.Modafinil administration was associated with administration was associated with significantly greater activation in the significantly greater activation in the anterior cingulate cortex during the anterior cingulate cortex during the working memory task.The anterior working memory task.The anterior cingulate cortex signal correlated with cingulate cortex signal correlated with cognitive performance, although only a cognitive performance, although only a subset of patients exhibited 'enhancement'. subset of patients exhibited 'enhancement'.
Conclusions Conclusions Modafinil modulates
Modafinil modulates anterior cingulate cortex function in anterior cingulate cortex function in chronic schizophrenia but its beneficial chronic schizophrenia but its beneficial cognitive effects may be restricted to a cognitive effects may be restricted to a subset of patients requiring further subset of patients requiring further characterisation. characterisation.
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Schizophrenia is associated with wideSchizophrenia is associated with widespread cognitive impairments, some of spread cognitive impairments, some of which, such as those affecting memory which, such as those affecting memory and vigilance, have an impact upon indeand vigilance, have an impact upon independent living (Velligan pendent living (Velligan et al et al, 1997) . , 1997). Amelioration of such impairments might Amelioration of such impairments might improve the quality of life, therefore we improve the quality of life, therefore we studied the effects of a putative cognitive studied the effects of a putative cognitive enhancer, modafinil, upon prefrontal funcenhancer, modafinil, upon prefrontal function in people with chronic schizophrenia. tion in people with chronic schizophrenia. Modafinil (2-[(diphenylmethyl)sulphinyl] Modafinil (2-[(diphenylmethyl)sulphinyl] acetamide) is a novel agent that promotes acetamide) is a novel agent that promotes wakefulness and is licensed in the UK and wakefulness and is licensed in the UK and USA for the treatment of narcolepsy USA for the treatment of narcolepsy (Cephalon, 1999; US Modafinil in (Cephalon, 1999 ; US Modafinil in Narcolepsy Multicenter Study Group, Narcolepsy Multicenter Study Group, 2000; British Medical Association, 2004 ). 2000 British Medical Association, 2004 ). Its precise mode of action is uncertain, Its precise mode of action is uncertain, although in animal models it has been although in animal models it has been shown to elicit 'early gene' expression in shown to elicit 'early gene' expression in anterior hypothalamus (Lin anterior hypothalamus (Lin et al et al, 1996) , 1996) and anterior cingulate cortex (Scammell and anterior cingulate cortex (Scammell et et al al, 2000) , findings congruent with its , 2000), findings congruent with its properties. Very recently, modafinil has properties. Very recently, modafinil has been reported to enhance short-term verbal been reported to enhance short-term verbal memory in people with schizophrenia memory in people with schizophrenia (Turner (Turner et al et al, 2004) . , 2004).
METHOD METHOD
On the basis of animal studies, we chose to On the basis of animal studies, we chose to probe cognitive functions that would enprobe cognitive functions that would engage 'higher' executive regions, particularly gage 'higher' executive regions, particularly the anterior cingulate cortex (implicated in the anterior cingulate cortex (implicated in vigilance). However, in view of the vigilance). However, in view of the uncertain mechanism of action of modauncertain mechanism of action of modafinil, and emerging evidence of a possible finil, and emerging evidence of a possible risk of psychosis exacerbation (Narendran risk of psychosis exacerbation (Narendran et al et al, 2002) , we utilised a relatively small , 2002), we utilised a relatively small dose of drug. Our study was conducted dose of drug. 
Participants Participants
Right-handed males aged 18-60 years, Right-handed males aged 18-60 years, with premorbid IQ with premorbid IQ 4 470 on the National 70 on the National Adult Reading Test (NART; Nelson & Adult Reading Test (NART; Nelson & O'Connell, 1978) and a DSM-IV O'Connell, 1978) and a DSM-IV (American Psychiatric Association, 1994) (American Psychiatric Association, 1994) diagnosis of schizophrenia and prominent diagnosis of schizophrenia and prominent negative symptomatology (rating 3 on at negative symptomatology (rating 3 on at least one item of the Scale for the least one item of the Scale for the Assessment of Negative Symptoms (SANS); Assessment of Negative Symptoms (SANS); Andreasen, 1983) were included. Exclusion Andreasen, 1983) were included. Exclusion criteria were: prominent 'positive' symptocriteria were: prominent 'positive' symptomatology (marked delusions and/or hallucimatology (marked delusions and/or hallucinations); recent history of mental state nations); recent history of mental state instability; changes to psychotropic mediinstability; changes to psychotropic medication or admission to hospital within 3 cation or admission to hospital within 3 months of assessment; significant history months of assessment; significant history of neurological, endocrine or cardiovascuof neurological, endocrine or cardiovascular disorder; hypersensitivity to modafinil; lar disorder; hypersensitivity to modafinil; concurrent prescription of other stimulant concurrent prescription of other stimulant medication; concurrent substance misuse; medication; concurrent substance misuse; and contraindications to magnetic resoand contraindications to magnetic resonance imaging scanning (metallic implants, nance imaging scanning (metallic implants, foreign bodies and claustrophobia). foreign bodies and claustrophobia).
Thirty-two patients were approached Thirty-two patients were approached and 21 agreed to participate following a and 21 agreed to participate following a full explanation of the study. Nineteen of full explanation of the study. Nineteen of these satisfied detailed assessment of the inthese satisfied detailed assessment of the inclusion and exclusion criteria. Participants clusion and exclusion criteria. Participants underwent psychiatric (Brief Psychiatric underwent psychiatric (Brief Psychiatric Rating Scale; Overall & Gorham, 1962; Rating Scale; Overall & Gorham, 1962 Because the study was funded by an 'investigator-led study was funded by an 'investigator-led award' and was not a 'company-sponsored award' and was not a 'company-sponsored trial', research indemnity was provided by trial', research indemnity was provided by the Sheffield Care Trust (and reciprocally the Sheffield Care Trust (and reciprocally participating National Health Service participating National Health Service trusts) and clinical trial insurance was trusts) and clinical trial insurance was provided by the University of Sheffield. provided by the University of Sheffield.
Procedures Procedures
We utilised a randomised, double-blind We utilised a randomised, double-blind placebo-controlled crossover design. Patients placebo-controlled crossover design. Patients were studied on 2 days, 1 week apart. On were studied on 2 days, 1 week apart. On each day, patients received oral modafinil each day, patients received oral modafinil (100 mg) or placebo 2 h prior to functional (100 mg) or placebo 2 h prior to functional magnetic resonance imaging (fMRI) scanmagnetic resonance imaging (fMRI) scanning. Administration and scanning times were ning. Administration and scanning times were predicated on the drug's pharmacokinetics predicated on the drug's pharmacokinetics 5 5 5 5 Patients were required not to smoke or consume caffeine prior to scanning. They or consume caffeine prior to scanning. They were admitted for 24-h observation after were admitted for 24-h observation after the scanning procedure. The outcome the scanning procedure. The outcome measures were: a difference in fMRI signal, measures were: a difference in fMRI signal, during a working memory task, between during a working memory task, between the modafinil and placebo conditions; a the modafinil and placebo conditions; a difference in behavioural performance difference in behavioural performance (accuracy), during the same intra-scanner (accuracy), during the same intra-scanner task, between modafinil and placebo task, between modafinil and placebo conditions; and a patient-wise bivariate conditions; and a patient-wise bivariate correlation between the first two measures. correlation between the first two measures.
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Psychological paradigm Psychological paradigm
Inside the scanner, patients performed a Inside the scanner, patients performed a standard working memory task (the '2-standard working memory task (the '2-back'; Callicott back '; Callicott et al et al, 1998) . This difficult , 1998). This difficult task required subjects to monitor, update task required subjects to monitor, update and temporally 'tag' the contents of their and temporally 'tag' the contents of their working memory (Manoach, 2003) . A series working memory (Manoach, 2003) . A series of numbers (between 1 and 4) was preof numbers (between 1 and 4) was presented visually, in a pseudo-random order, sented visually, in a pseudo-random order, one every 2 s. Colour coding of these one every 2 s. Colour coding of these stimuli cued patients to indicate (by pressing stimuli cued patients to indicate (by pressing a button) either which number was cura button) either which number was currently presented on the screen (the '0-back'; rently presented on the screen (the '0-back'; baseline condition) or which number had baseline condition) or which number had been presented two trials earlier (i.e. the been presented two trials earlier (i.e. the '2-back'; active condition). Stimuli were '2-back'; active condition). Stimuli were delivered using Presentation (Neurobehadelivered using Presentation (Neurobehavioral Systems Inc, California, USA) softvioral Systems Inc, California, USA) software running on a personal computer via ware running on a personal computer via a video projector and mirror located inside a video projector and mirror located inside the scanner bore. Patients responded by the scanner bore. Patients responded by pressing one of four buttons on an intrapressing one of four buttons on an intrascanner box optically connected to the scanner box optically connected to the computer system via an interface (New computer system via an interface (New Micros Inc, Micros Inc, Texas, USA). In an alternatTexas, USA). In an alternating, blocked ing, blocked 0-back/2-back design, 15 con-0-back/2-back design, 15 consecutive '0-back' stimuli (lasting 30 s) were secutive '0-back' stimuli (lasting 30 s) were followed by 15 consecutive '2-back' stimuli followed by 15 consecutive '2-back' stimuli (also lasting 30 s). This sequence was re-(also lasting 30 s). This sequence was repeated six times; hence the functional scans peated six times; hence the functional scans lasted 6 min in total. lasted 6 min in total.
Patients practised the task prior to enPatients practised the task prior to entering the scanner but did so only three tering the scanner but did so only three times in order to minimise any automation times in order to minimise any automation of the procedure. Different performance of the procedure. Different performance levels have been permitted in previous levels have been permitted in previous studies. Some have incorporated a wide studies. Some have incorporated a wide range of accuracy among patients with range of accuracy among patients with schizophrenia (Callicott schizophrenia (Callicott et al et al, 1998 (Callicott et al et al, , where , 1998 , where performance was relatively poor; Meyerperformance was relatively poor; MeyerLindenberg Lindenberg et al et al, 2001; Bertolino , 2001; Bertolino et al et al, , 2003) whereas others have set more 2003) whereas others have set more stringent thresholds (Callicott stringent thresholds (Callicott et al et al, 2000 (Callicott et al et al, , , 2000 (Callicott et al et al, , 2003 . Comparison with a healthy control 2003). Comparison with a healthy control group necessarily requires comparable group necessarily requires comparable levels of performance across the groups, levels of performance across the groups, but in our study we wished to compare but in our study we wished to compare patients' performances against themselves patients' performances against themselves (on and off modafinil). Hence, we allowed (on and off modafinil). Hence, we allowed for a range of performance accuracy. This for a range of performance accuracy. This was partly pragmatic, given that we were was partly pragmatic, given that we were deliberately studying people with chronic deliberately studying people with chronic schizophrenia and prominent negative schizophrenia and prominent negative symptomatology (the likely recipients of symptomatology (the likely recipients of putative cognitive enhancers), but also putative cognitive enhancers), but also design-led because we required a design-led because we required a range range of of performance across the group to detect performance across the group to detect changes in performance within subjects changes in performance within subjects exposed to modafinil (hence avoiding exposed to modafinil (hence avoiding 'ceiling effects') and to allow for 'ceiling effects') and to allow for post hoc post hoc correlations with performance correlations with performance per se per se (Manoach (Manoach et al et al, 1999; Callicott , 1999; Callicott et al et al, , 2000 Callicott et al et al, , , 2003 . 2000, 2003) .
Functional image acquisition and analysis Functional image acquisition and analysis
At each of 120 functional imaging time At each of 120 functional imaging time points, 32 points, 326 64 mm contiguous T 4 mm contiguous T 2 2 *-weighted *-weighted slices were acquired using echo-planar slices were acquired using echo-planar imaging on a 1.5 T system (Eclipse, Philips, imaging on a 1.5 T system (Eclipse, Philips, Ohio) at Sheffield University (repetition Ohio) at Sheffield University (repetition time time¼3 s; echo time 3 s; echo time¼40 ms; field of view 40 ms; field of view¼ 240 mm; in-plane matrix 240 mm; in-plane matrix¼128 1286 6128). 128).
Images were analysed using SPM99 Images were analysed using SPM99 (http://www.fil.ion.ucl.ac.uk/). The blood (http://www.fil.ion.ucl.ac.uk/). The blood oxygenation level-dependent (BOLD) resoxygenation level-dependent (BOLD) response that is measured by fMRI is thought ponse that is measured by fMRI is thought to represent a vascular marker of neuronal to represent a vascular marker of neuronal activation (Logothetis activation (Logothetis et al et al, 2001) . Follow-, 2001 ). Following timing and movement correction, ing timing and movement correction, spatial normalisation and smoothing with spatial normalisation and smoothing with a Gaussian kernel of 6 mm full width at a Gaussian kernel of 6 mm full width at half-maximum (Friston half-maximum (Friston et al et al, 1995) , we , 1995), we used a 'boxcar' wave convolved with a used a 'boxcar' wave convolved with a synthetic haemodynamic response function synthetic haemodynamic response function to model the BOLD response. Each patient to model the BOLD response. Each patient had two fMRI data-sets (modafinil and had two fMRI data-sets (modafinil and placebo); for each individual data-set, a placebo); for each individual data-set, a first-level voxel-wise contrast of activation first-level voxel-wise contrast of activation during the working memory during the working memory v v. baseline . baseline was undertaken. This generated contrast was undertaken. This generated contrast images, which were then used in a secondimages, which were then used in a secondorder (random-effects) group analysis. order (random-effects) group analysis.
Random-effects analyses allow quantiRandom-effects analyses allow quantitative inferences to be drawn regarding tative inferences to be drawn regarding the average behaviour of the population the average behaviour of the population from which patients are selected, across from which patients are selected, across different scanning sessions. Such an analydifferent scanning sessions. Such an analysis is mandatory in psychopharmacological sis is mandatory in psychopharmacological designs where the main effect of interest designs where the main effect of interest exists only exists only between between distinct scanning distinct scanning sessions (i.e., modafinil sessions (i.e., modafinil v v. placebo; Friston . placebo; Friston et al et al, 1999) . Individual contrast images , 1999). Individual contrast images were entered as data points in a wholewere entered as data points in a wholegroup analysis of covariance (ANCOVA) group analysis of covariance (ANCOVA) that compared brain activation during that compared brain activation during working memory working memory v v. baseline conditions . baseline conditions on on modafinil modafinil with activation during working with activation during working memory memory v v. baseline . baseline on placebo on placebo. Order of . Order of scanning (whether modafinil was received scanning (whether modafinil was received on day 1 or day 2) comprised the 'nuisance' on day 1 or day 2) comprised the 'nuisance' covariate. This produced a group paracovariate. This produced a group parametric brain map of metric brain map of t t-statistics, in the -statistics, in the stereotactic space of the Montreal stereotactic space of the Montreal Neurological Institute (MNI; Evans Neurological Institute (MNI; Evans et al et al, , 1993) , showing brain areas more activated 1993), showing brain areas more activated during working memory than baseline during working memory than baseline conditions on modafinil compared with conditions on modafinil compared with placebo. We emphasise that intra-session placebo. We emphasise that intra-session effects (working memory effects (working memory v v. baseline) were . baseline) were modelled at the first level but that the main modelled at the first level but that the main inter-session effect (modafinil inter-session effect (modafinil v v. placebo) . placebo) was modelled in the second-level (random was modelled in the second-level (random effects) analysis. effects) analysis.
We also produced two subsidiary brain We also produced two subsidiary brain maps, demonstrating brain areas more acmaps, demonstrating brain areas more activated during working memory than basetivated during working memory than baseline on placebo only and modafinil only, line on placebo only and modafinil only, using two single group ANCOVAs (as using two single group ANCOVAs (as before, with scanning order as 'nuisance' before, with scanning order as 'nuisance' covariate). Hence, we were able to ensure covariate). Hence, we were able to ensure that the expected pattern of cortical activthat the expected pattern of cortical activation was obtained during the '2-back' ation was obtained during the '2-back' irrespective of drug/placebo condition. irrespective of drug/placebo condition.
Because our study was hypothesis Because our study was hypothesis driven, we set our significance threshold driven, we set our significance threshold at at P P5 50.01, uncorrected for height and 0.01, uncorrected for height and extent of activation. We also designated extent of activation. We also designated a a small volume (sphere of diameter small volume (sphere of diameter¼ 10 mm) that could be used to correct for 10 mm) that could be used to correct for multiple comparisons (family-wise error multiple comparisons (family-wise error method) should activation in the method) should activation in the a priori a priori region of interest (anterior cingulate cortex) region of interest (anterior cingulate cortex) be observed at the uncorrected threshold. be observed at the uncorrected threshold. For the purposes of reporting and neuroFor the purposes of reporting and neuroanatomical labelling, the stereotactic coordianatomical labelling, the stereotactic coordinates of activated areas were transformed nates of activated areas were transformed from MNI space into the system of from MNI space into the system of Talairach & Tournoux (1988) . Talairach & Tournoux (1988) .
Brain activation/behavioural performance Brain activation/behavioural performance correlations correlations
For each patient we calculated a measure of For each patient we calculated a measure of performance (percentage accuracy) during performance (percentage accuracy) during the working memory task on both study the working memory task on both study days, and hence a 'difference' score days, and hence a 'difference' score between the modafinil and placebo conbetween the modafinil and placebo conditions. Taking the anterior cingulate ditions. Taking the anterior cingulate cortex as a region of interest, we also cortex as a region of interest, we also estimated the magnitude of fMRI signal estimated the magnitude of fMRI signal change (derived from the 'beta' parameters change (derived from the 'beta' parameters in SPM99) during the working memory in SPM99) during the working memory task ( task (v v. baseline) on both study days. For . baseline) on both study days. For each patient, this allowed us to calculate each patient, this allowed us to calculate the difference in the anterior cingulate the difference in the anterior cingulate cortex signal change, during the working cortex signal change, during the working memory task, between modafinil and memory task, between modafinil and placebo conditions. We then ran patientplacebo conditions. We then ran patientwise bivariate correlations between the wise bivariate correlations between the difference in behavioural performance on difference in behavioural performance on modafinil modafinil v v. placebo and the difference in . placebo and the difference in anterior cingulate cortex signal change on anterior cingulate cortex signal change on modafinil modafinil v v. placebo. . placebo.
RESULTS RESULTS
Adverse events and image quality Adverse events and image quality
We analysed data from 17 of the 19 patients We analysed data from 17 of the 19 patients entering the study. One patient did not entering the study. One patient did not complete the study due to relapse of acute complete the study due to relapse of acute psychosis 4 days after the first scanning psychosis 4 days after the first scanning day. Ethical considerations required discloday. Ethical considerations required disclosure of his randomisation status, revealing sure of his randomisation status, revealing that he had received modafinil. This was that he had received modafinil. This was the only clinically significant adverse event the only clinically significant adverse event that occurred during the study. Data from that occurred during the study. Data from another patient could not be analysed another patient could not be analysed because of technical problems with his because of technical problems with his second-session fMRI images. second-session fMRI images.
Demographic data Demographic data
Patients were predominantly middle-aged Patients were predominantly middle-aged males who had been ill for approximately males who had been ill for approximately 15 years (Table 1) . Sixteen were single; 15 years (Table 1) . Sixteen were single; none was in paid employment but five none was in paid employment but five performed voluntary work; 16 received performed voluntary work; 16 received maximum disability living allowance; eight maximum disability living allowance; eight lived in their 'own' accommodation; three lived in their 'own' accommodation; three with parents, two in supported group prowith parents, two in supported group projects and four in rehabilitation units. Most jects and four in rehabilitation units. Most patients were receiving oral antipsychotics patients were receiving oral antipsychotics ( (n n¼13), which were 'atypical' in all but 13), which were 'atypical' in all but one case. Four patients received intramusone case. Four patients received intramuscular ('typical') depot medication. Of these cular ('typical') depot medication. Of these 17 patients, none changed medication 17 patients, none changed medication during the study period. Nine patients during the study period. Nine patients received modafinil on day 1 and placebo received modafinil on day 1 and placebo on day 2; eight received the reverse. on day 2; eight received the reverse.
Behavioural measures Behavioural measures
Statistical comparisons were prespecified, Statistical comparisons were prespecified, except where indicated. We used nonexcept where indicated. We used nonparametric tests to analyse the group beparametric tests to analyse the group behavioural (accuracy) data during the havioural (accuracy) data during the working memory task under placebo and working memory task under placebo and modafinil conditions (these were not normodafinil conditions (these were not normally distributed). Under placebo condimally distributed). Under placebo conditions, response accuracy for the control tions, response accuracy for the control '0-back' condition was 19-88% (median '0-back' condition was 19-88% (median 71%) and did not differ significantly from 71%) and did not differ significantly from that on modafinil: range 11-99%, median that on modafinil: range 11-99%, median 71% (Wilcoxon signed rank test; 71% (Wilcoxon signed rank test; Z Z¼0.12; 0.12; P P¼0.91). Under placebo conditions, re-0.91). Under placebo conditions, response accuracy for the '2-back' task was sponse accuracy for the '2-back' task was 5-85% (median 26%) 5-85% (median 26%) and did not differ and did not differ significantly from that on modafinil: range significantly from that on modafinil: range 4-79%, median 22% (Wilcoxon signed 4-79%, median 22% (Wilcoxon signed rank test; rank test; Z Z¼0.97; 0.97; P P¼0.33). 0.33).
Brain activations Brain activations
Functional image analysis showed that on Functional image analysis showed that on both the modafinil and placebo days the both the modafinil and placebo days the patients exhibited activations during the patients exhibited activations during the 2-back condition (relative to the 0-back) 2-back condition (relative to the 0-back) in predicted brain regions (Tables 2 and 3) , in predicted brain regions (Tables 2 and 3) ). Functional image analysis comparing Functional image analysis comparing the modafinil with the placebo condition the modafinil with the placebo condition revealed that working memory task perforrevealed that working memory task performance was associated with significantly mance was associated with significantly 5 7 5 7 Talairach & Tournoux (1988) ; 'Z Z' reflects peak statistical 'height' ' reflects peak statistical 'height' of the most activated voxel in each cluster; 'voxels' indicates total number of voxels exceeding height threshold of the most activated voxel in each cluster; 'voxels' indicates total number of voxels exceeding height threshold P P5 50.01 0.01 in each cluster. in each cluster.
greater activation solely in the anterior greater activation solely in the anterior cingulate cortex ( Fig. 1 ; Talairach coordicingulate cortex ( Fig. 1 ; Talairach coordinates: nates: x x¼6 mm, 6 mm, y y¼38 mm, 38 mm, z z¼15 mm; 131 15 mm; 131 supra-threshold voxels; peak supra-threshold voxels; peak Z Z score score¼3.14; 3.14; P P5 50.01, uncorrected, for height and extent 0.01, uncorrected, for height and extent of activation). This activation remained of activation). This activation remained significant after correction for multiple significant after correction for multiple comparisons within the defined region of comparisons within the defined region of interest ( interest (P P5 50.05). Examining the separate 0.05). Examining the separate modafinil and placebo brain maps (of the modafinil and placebo brain maps (of the working memory working memory v v. baseline contrast) . baseline contrast) confirmed that this focal difference was confirmed that this focal difference was due to greater anterior cingulate cortex due to greater anterior cingulate cortex activation during working memory than activation during working memory than baseline performance on modafinil baseline performance on modafinil ( (x x¼6 mm, 6 mm, y y¼38 mm, 38 mm, z z¼18 mm; 50 voxels; 18 mm; 50 voxels; Z Z¼3.79; 3.79; P P5 50.01, uncorrected, for height 0.01, uncorrected, for height of activation), and not the converse, of activation), and not the converse, namely, greater activation during baseline namely, greater activation during baseline than working memory on placebo. than working memory on placebo.
Patient-wise differences in anterior Patient-wise differences in anterior cingulate cortex activation (Fig. 1) and cingulate cortex activation (Fig. 1) and behavioural performance (between modabehavioural performance (between modafinil and placebo conditions) were posifinil and placebo conditions) were positively and significantly correlated ( Fig. 2 ; tively and significantly correlated ( Fig. 2; Spearman's Spearman's r r¼0.42; one-tailed 0.42; one-tailed P P5 50.05). 0.05). However, this correlation did not reflect a However, this correlation did not reflect a straightforward relationship between imstraightforward relationship between improved activation and improved perforproved activation and improved performance. Rather, it reflected an increased mance. Rather, it reflected an increased fMRI signal in the majority of patients fMRI signal in the majority of patients during the modafinil session, with conduring the modafinil session, with concomitant improvement of memory perforcomitant improvement of memory performance in half and a decreased signal in a mance in half and a decreased signal in a minority of patients (in response to modaminority of patients (in response to modafinil), most of whom exhibited reduced finil), most of whom exhibited reduced performance on the drug (Fig. 2) . Hence, performance on the drug (Fig. 2) . Hence, for the patient group as a whole there was for the patient group as a whole there was a relationship between the degree to which a relationship between the degree to which anterior cingulate cortex activation, during anterior cingulate cortex activation, during the memory task, was modulated (increased/ the memory task, was modulated (increased/ decreased) by the drug and their level of decreased) by the drug and their level of cognitive performance. Although a subcognitive performance. Although a subgroup of patients exhibited enhanced cognigroup of patients exhibited enhanced cognition (in association with increased anterior tion (in association with increased anterior cingulate cortex activation), no patient cingulate cortex activation), no patient exhibiting reduced anterior cingulate cortex exhibiting reduced anterior cingulate cortex activity improved cognitively. activity improved cognitively.
Post hoc Post hoc examination of the data examination of the data revealed that of the five patients exhibiting revealed that of the five patients exhibiting improvements of both anterior cingulate improvements of both anterior cingulate cortex fMRI signal and 2-back perforcortex fMRI signal and 2-back performance, four were receiving 'typical' neuromance, four were receiving 'typical' neuroleptics (depot or sulpiride) and one was leptics (depot or sulpiride) and one was receiving olanzapine. That is, of five receiving olanzapine. That is, of five patients who received 'typicals' the majorpatients who received 'typicals' the majority responded positively to modafinil (both ity responded positively to modafinil (both physiologically and cognitively). Conversely, physiologically and cognitively). Conversely, of 12 patients receiving 'atypicals' only one of 12 patients receiving 'atypicals' only one exhibited this pattern. Moreover, a exhibited this pattern. Moreover, a post post hoc hoc analysis confirmed that the positive analysis confirmed that the positive correlation between anterior cingulate correlation between anterior cingulate cortex signal and performance change was cortex signal and performance change was most significant in the five patients receivmost significant in the five patients receiving 'typical' antipsychotics (Spearman's ing 'typical' antipsychotics (Spearman's r r¼1.00, 1.00, P P not calculated). Conversely, not calculated). Conversely, 5 8 5 8 Talairach & Tournoux (1988) ; 'Z Z' reflects peak statistical 'height'of ' reflects peak statistical 'height' of the most activated voxel in each cluster; 'voxels' indicates total number of voxels exceeding height threshold the most activated voxel in each cluster; 'voxels' indicates total number of voxels exceeding height threshold P P5 50.01 in 0.01 in each cluster. each cluster. 1. Although not significant for extent of activation in the modafinil-only analysis, this distinct area of anterior cingulate 1. Although not significant for extent of activation in the modafinil-only analysis, this distinct area of anterior cingulate cortex activation represents the region of 'most difference' between modafinil and placebo conditions and, hence, corcortex activation represents the region of 'most difference' between modafinil and placebo conditions and, hence, corresponds to the basis for the activation observed in the main modafinil responds to the basis for the activation observed in the main modafinil v v. placebo contrast (the coordinates were also . placebo contrast (the coordinates were also used to define a region of interest within which correction for multiple comparisons was performed; see text and Fig.1 ). used to define a region of interest within which correction for multiple comparisons was performed; see text and Fig.1 ). 2. Large clusters and their anatomically distinct foci. 2. Large clusters and their anatomically distinct foci. Fig. 1 The brain area (anterior cingulate cortex) that exhibited greater activation during a working memory The brain area (anterior cingulate cortex) that exhibited greater activation during a working memory task on modafinil than on placebo. Group data displayed against a 'canonical' T task on modafinil than on placebo. Group data displayed against a 'canonical' T 1 1 -weighted image (upper panels); -weighted image (upper panels); supra-threshold voxels are shown in yellow ( supra-threshold voxels are shown in yellow (P P5 50.01). In order to demonstrate the regional specificity of this 0.01). In order to demonstrate the regional specificity of this finding the data are also displayed at the same statistical threshold within a 'glass brain' (lower panels). finding the data are also displayed at the same statistical threshold within a 'glass brain' (lower panels).
when these patients were excluded from the when these patients were excluded from the group analysis, the latter was no longer group analysis, the latter was no longer significant (for 12 patients receiving significant (for 12 patients receiving 'atypicals', 'atypicals', r r¼0.03; one-tailed 0.03; one-tailed P P¼0.47). 0.47). Exclusion of those subjects whose perforExclusion of those subjects whose performance was at the level of chance on placebo mance was at the level of chance on placebo led to exclusion of three of the four subjects led to exclusion of three of the four subjects receiving depots and a reduction of the receiving depots and a reduction of the anterior cingulate cortex/performance anterior cingulate cortex/performance correlation to trend significance ( correlation to trend significance (r r¼0.58; 0.58; one-tailed one-tailed P P¼0.06). Hence, it is possible 0.06). Hence, it is possible that those receiving depot medication that those receiving depot medication derived the greatest benefit from modafinil derived the greatest benefit from modafinil (perhaps as a consequence of greater initial (perhaps as a consequence of greater initial deficit) and contributed most to the findings. deficit) and contributed most to the findings.
We further investigated this We further investigated this post hoc post hoc 'deficit/benefit' hypothesis and found that 'deficit/benefit' hypothesis and found that those exhibiting improved working memthose exhibiting improved working memory performance on modafinil had demonory performance on modafinil had demonstrated significantly worse performance on strated significantly worse performance on a verbal fluency task at initial assessment a verbal fluency task at initial assessment compared with other patients. Responders compared with other patients. Responders generated 7-18 words in 1 min (median generated 7-18 words in 1 min (median 10); non-responders generated 4-25 words, 10); non-responders generated 4-25 words, median 11.5 (Mann-Whitney median 11.5 (Mann-Whitney U U-test; -test; Z Z¼2.19; 2.19; P P¼0.03). There were no correla-0.03). There were no correlations between intra-scanner working tions between intra-scanner working memory task performance and specific memory task performance and specific symptom ratings. symptom ratings.
Finally, by way of validating our Finally, by way of validating our sample against those described in successive sample against those described in successive reports, which have repeatedly described reports, which have repeatedly described positive correlations between 2-back accupositive correlations between 2-back accuracy and right dorsolateral prefrontal corracy and right dorsolateral prefrontal cortex activity in people with schizophrenia tex activity in people with schizophrenia compared with 'normals' (Callicott compared with 'normals' (Callicott et al et al, , 1999 (Callicott et al et al, , , 2000 , we examined the correlates 1999, 2000), we examined the correlates of performance of performance per se per se on the 2-back task. on the 2-back task. We found the right dorsolateral prefrontal We found the right dorsolateral prefrontal cortex implicated under both conditions cortex implicated under both conditions (placebo; (placebo; 
DISCUSSION DISCUSSION
Neural response Neural response
We administered a single low dose of We administered a single low dose of modafinil to people with chronic schizomodafinil to people with chronic schizophrenia and assessed working memory durphrenia and assessed working memory during fMRI. Our data reveal a specific effect ing fMRI. Our data reveal a specific effect of the drug upon an area of the frontal lobe of the drug upon an area of the frontal lobe called the anterior cingulate cortex. Imporcalled the anterior cingulate cortex. Importantly, this effect was specific to the active tantly, this effect was specific to the active memory condition and not the baseline memory condition and not the baseline state. Anterior cingulate cortex is involved state. Anterior cingulate cortex is involved in a wide range of executive functions in a wide range of executive functions (Bush (Bush et al et al, 2000) and has been activated , 2000) and has been activated during working memory proto during working memory protocols in precols in previous studies (Callicott vious studies (Callicott et al et al, 2000 (Callicott et al et al, , 2003 , 2000 , 2003 Meyer-Lindenberg Meyer-Lindenberg et al et al, 2001) . Its activ-, 2001) . Its activation in people with chronic schizophrenia ation in people with chronic schizophrenia appears to be enhanced by modafinil appears to be enhanced by modafinil (Fig. 1) . (Fig. 1) .
Cognitive response Cognitive response
Despite enhanced anterior cingulate cortex Despite enhanced anterior cingulate cortex activation at the group level (during workactivation at the group level (during working memory performance), most of our ing memory performance), most of our patients did not exhibit enhanced cognipatients did not exhibit enhanced cognition. For the group as a whole there was tion. For the group as a whole there was no effect of modafinil upon working no effect of modafinil upon working memory (on this protocol). Therefore it memory (on this protocol). Therefore it might be posited that increased anterior might be posited that increased anterior cingulate cortex activation is either unrecingulate cortex activation is either unrelated to cognition or indicative of reduced lated to cognition or indicative of reduced efficiency of cognitive processing (Callicott efficiency of cognitive processing (Callicott et al et al, 2000; Manoach, 2003) . If greater , 2000; Manoach, 2003) . If greater anterior cingulate cortex activation occurs anterior cingulate cortex activation occurs without an increase in cognitive without an increase in cognitive performance then brain function might be performance then brain function might be said to be less efficient in the presence of said to be less efficient in the presence of modafinil. However, it is important to note modafinil. However, it is important to note that cognitive function did improve in a that cognitive function did improve in a minority of patients, and that although it minority of patients, and that although it might be posited that this is to be expected might be posited that this is to be expected statistically (as merely a manifestation of statistically (as merely a manifestation of variation around the mean), there is a variation around the mean), there is a feature of the data that runs counter to this feature of the data that runs counter to this interpretation. This is the interpretation. This is the positive positive correlacorrelation between anterior cingulate cortex tion between anterior cingulate cortex activation and cognitive improvement activation and cognitive improvement (Fig. 2) . If modafinil simply made anterior (Fig. 2) . If modafinil simply made anterior cingulate cortex function less efficient, then cingulate cortex function less efficient, then we should expect such a correlation to be we should expect such a correlation to be negative negative. The positive correlation implies . The positive correlation implies that the magnitude of anterior cingulate that the magnitude of anterior cingulate cortex activation and cognitive performance cortex activation and cognitive performance are indeed related in the context of modafiare indeed related in the context of modafinil exposure; those exhibiting the greater nil exposure; those exhibiting the greater anterior cingulate cortex response also anterior cingulate cortex response also exhibit the greater cognitive enhancement exhibit the greater cognitive enhancement (of working memory). (of working memory).
Accounting for 'responders' Accounting for 'responders'
It is of interest that those exhibiting greater It is of interest that those exhibiting greater physiological and cognitive response to physiological and cognitive response to modafinil tended to be those who were modafinil tended to be those who were receiving 'typical' neuroleptic medications receiving 'typical' neuroleptic medications (depots and sulpiride). The numbers are (depots and sulpiride). The numbers are small but there may be a rationale for this small but there may be a rationale for this finding. The neurotransmitter systems finding. The neurotransmitter systems implicated in the promotion of wakefulness implicated in the promotion of wakefulness by modafinil include the dopaminergic and by modafinil include the dopaminergic and serotonergic systems. Although antipsychoserotonergic systems. Although antipsychotics share antagonism of the dopaminergic tics share antagonism of the dopaminergic system (especially at the D2 receptor), the system (especially at the D2 receptor), the typicals and atypicals differ in their affitypicals and atypicals differ in their affinities for other receptors, particularly nities for other receptors, particularly 5HT 5HT 2A 2A (Keefe (Keefe et al et al, 1999) . In animal , 1999). In animal models modafinil's effect of increasing models modafinil's effect of increasing alertness is attenuated by 5HT alertness is attenuated by 5HT 2A 2A antagonantagonism (Shelton ism (Shelton et al et al, 1995) , hence, it is , 1995), hence, it is possible that atypical antipsychotic treatpossible that atypical antipsychotic treatment (if antagonising 5HT ment (if antagonising 5HT 2A 2A ) might con-) might constrain the cognotropic effects of modafinil strain the cognotropic effects of modafinil (a hypothesis deserving further study). (a hypothesis deserving further study). Alternatively, the ability of atypicals Alternatively, the ability of atypicals 
Safety Safety
There are a number of caveats to our study There are a number of caveats to our study and its findings. First, for the reasons and its findings. First, for the reasons described, we deliberately utilised a reladescribed, we deliberately utilised a relatively low dose of modafinil. This may have tively low dose of modafinil. This may have been sub-optimal. Nevertheless, one of our been sub-optimal. Nevertheless, one of our participants underwent psychotic relapse participants underwent psychotic relapse 4 days post-drug. We cannot determine 4 days post-drug. We cannot determine whether modafinil was whether modafinil was responsible.
responsible. Although covert non-adherence Although covert non-adherence to concurto concurrent medication cannot be excluded (he rent medication cannot be excluded (he was receiving an oral antipsychotic), we was receiving an oral antipsychotic), we must be wary of seeking to exculpate the must be wary of seeking to exculpate the test medication. However, a psychotic reactest medication. However, a psychotic reaction to a tion to a single single dose of modafinil is unpredose of modafinil is unprecedented (to our knowledge), although cedented (to our knowledge), although there are cases of psychosis emerging there are cases of psychosis emerging de de novo novo in those receiving multiple doses.
in those receiving multiple doses. The manufacturer's prescribing inforThe manufacturer's prescribing information reports that: 'one healthy male mation reports that: 'one healthy male volunteer developed ideas of reference, volunteer developed ideas of reference, paranoid delusions, and auditory hallucinaparanoid delusions, and auditory hallucinations in association with multiple daily tions in association with multiple daily 600 mg doses of [modafinil] and sleep 600 mg doses of [modafinil] and sleep deprivation. There was no evidence of psydeprivation. There was no evidence of psychosis 36 hours after drug discontinuation.' chosis 36 hours after drug discontinuation.' (Cephalon, 1999) . The (Cephalon, 1999) . The British National British National Formulary Formulary does not mention psychosis as does not mention psychosis as either a contraindication to or a conseeither a contraindication to or a consequence of modafinil exposure. quence of modafinil exposure.
In a recent study of 20 patients with In a recent study of 20 patients with schizophrenia exposed to a single dose of schizophrenia exposed to a single dose of 200 mg of modafinil, the drug elicited no 200 mg of modafinil, the drug elicited no exacerbation of psychosis (Turner exacerbation of psychosis (Turner et al et al, , 2004) . However, there are anecdotal ac-2004). However, there are anecdotal accounts of schizophrenic relapse following counts of schizophrenic relapse following repeated dosing (Narendran repeated dosing (Narendran et al et al, 2002; , 2002; Rosenthal & Bryant, 2003) . Further Rosenthal & Bryant, 2003) . Further multi-dosing studies in other centres may multi-dosing studies in other centres may help to clarify the magnitude of such a help to clarify the magnitude of such a putative risk. putative risk. Patients with chronic schizophrenia exhibited increased anterior cingulate activation in response to modafinil while performing a working memory protocol; activation in response to modafinil while performing a working memory protocol; some also exhibited improved memory performance. some also exhibited improved memory performance.
& & Of the patients exhibiting improved memory performance on modafinil, most Of the patients exhibiting improved memory performance on modafinil, most were receiving concomitant 'typical' antipsychotic medication. were receiving concomitant 'typical' antipsychotic medication.
LIMITATIONS LIMITATIONS
& & As in many neuroimaging studies, the number of subjects examined is relatively As in many neuroimaging studies, the number of subjects examined is relatively small. small. 
